Search Bar & Filters
Found 87 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NT-101, a topical eye drop solution, in treating patients with wet age-related macular degeneration AMD. This phase 2 study is randomized, double-blind, placebo-controlled, and conducted at multiple centers. It aims to compare the effects of NT-101 versus placebo on vision and eye health over a 12-week treatment period. Participants will be randomly assigned to receive either NT-101 ophthalmic solution or a placebo, both administered as two drops into the affected eye twice daily for 12 weeks. The study includes a 4-week screening phase, followed by treatment, and a 4-week follow-up after treatment ends. Visits for assessments occur at baseline, Weeks 4, 8, and 12, with an additional visit if participants discontinue early. Throughout the study, participants will undergo various eye examinations such as best corrected visual acuity BCVA, slit-lamp exams, intraocular pressure measurements, optical coherence tomography OCT, and retinal imaging including fluorescein angiography. Safety is monitored by recording adverse events at each visit. The main outcome measured is the change in visual acuity at Week 12 compared to before treatment, with secondary measures including eye structure changes and safety up to Week 16.
Actively Recruiting
Researchers are studying the safety and effectiveness of intravitreal KSI-101 injections in adults with macular edema caused by inflammation, called Macular Edema Secondary to Inflammation MESI. This Phase 3 clinical trial aims to evaluate how well KSI-101 works compared to a sham injection in improving vision for people with this condition. Participants will receive one of three treatments KSI-101 at 5 mg or 10 mg doses injected into the eye every 4 weeks for six months, followed by dosing tailored to individual needs, or a sham injection following the same schedule. The study is randomized, double-masked, and controlled to ensure unbiased results. During the trial, participants will undergo vision tests to measure changes in best-corrected visual acuity BCVA over 24 weeks. Researchers will monitor safety and treatment effects throughout the study. The trial is expected to run until November 2027, with participants receiving regular assessments and follow-ups to track their eye health and response to treatment.
Actively Recruiting
Researchers are conducting a Phase 3 clinical trial to evaluate the safety and effectiveness of intravitreal KSI-101 in adults with macular edema caused by inflammation, known as Macular Edema Secondary to Inflammation MESI. The study aims to understand how well this treatment works compared to a sham injection in improving vision and reducing eye swelling related to this condition. Participants are randomly assigned to receive one of three treatments an intravitreal injection of KSI-101 at either 5 mg or 10 mg doses once every four weeks for six months, followed by personalized dosing schedules, or a sham injection on the same schedule. The injections are given directly into the eye, and the study is double-masked to ensure unbiased results. During the study, participants will undergo regular eye exams to measure visual acuity and eye thickness using specialized imaging. The main outcome is the change in best corrected visual acuity at 24 weeks. Researchers will also monitor the proportion of participants who show improvement in vision over this period. The trial includes safety assessments and will continue until August 2027, with detailed monitoring throughout the treatment and follow-up phases.
Actively Recruiting
Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.
Actively Recruiting
This research aims to compare two approaches for treating previously untreated amblyopia in children aged 3 to under 13 years. It evaluates whether using glasses and patching at the same time leads to similar improvements in vision as first using glasses alone, followed by patching only if needed. The trial focuses on children with amblyopia caused by differences in eye alignment or prescription errors. Children will be assigned randomly to one of two treatment groups one group will wear glasses full-time and add patching for 2 hours daily only if there is no improvement after glasses alone the other group will wear glasses and patch the weaker eye for 2 hours daily at the same time from the start. Vision tests will be done at baseline and follow-up visits every 8 weeks for up to 56 weeks. Participants will have their distance visual acuity measured with trial frames before and after getting their glasses to confirm eligibility. During the study, vision will be monitored to classify improvement or stability, guiding whether patching is needed in the sequential group. Outcomes include changes in vision clarity after 56 weeks and quality-of-life assessments. Regular visits help track progress and safety until study completion.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of a one-time intravitreal injection of SAR446597 in people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This Phase 12, two-part, multicenter study aims to understand how the treatment works and its potential benefits over approximately two years, followed by an additional three-year extended follow-up period. Participants will receive a single injection of SAR446597 into the eye or a sham injection, depending on the study part and dose group. Multiple dose levels of SAR446597 will be tested in different participant cohorts, with some receiving the active treatment and others receiving a sham as a control. Part I is open-label, while Part II involves randomized dosing and sham control groups. During the study, participants will be monitored for treatment side effects, changes in vision, and the size of GA lesions using visual acuity tests and lesion measurements at baseline, one year, and two years. Safety assessments will continue through the extended follow-up phase. The study also tracks serious and non-serious adverse events up to two years after treatment, with a total study duration of about five years per participant.
Actively Recruiting
Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.
1-10 of 87
1